



# PROVIDER *bulletin*

December 30, 2019

Dear Provider:

Diabetic medication reminders.

Currently there are two manufacturers making insulin lispro. Admelog is the preferred manufacturer of the two brands. As both Admelog and Humalog are the same product clinically, the most cost effective manufacturer will be formulary. The two branded drugs are not allowed to substitute without an approval from the provider in accordance to FDA rules. It would be helpful for prescriptions to be written for insulin lispro and then pharmacies may select any manufacturer. As of **October 1, 2019**, only Admelog will be authorized.

**Adlyxin:** Allowed after 90 days of SGLT-2 therapy. Lowest cost GLP-1 and a component of Soliqua.

**Soliqua:** Step Therapy. Requires prior use of Basaglar or GLP-1. Preferred if one is requiring to be on basal insulin and GLP-1 therapy.

**SGLT-2:** New starts and/or breaks in therapy for SGLT-2 therapy should consider **Steglatro/Segluromet** as it is preferred. If atherosclerotic cardiovascular disease is being managed as well, consider Jardiance/Synjardy. As of **October 1, 2019**, only **Steglatro/Segluromet** and Jardiance/Synjardy will be authorized.

**DPP-4:** New starts and/or breaks in therapy need to consider alogliptin. Consider **alogliptin** in place of other DPP-4's as clinically appropriate. It is the only one in the class available as a generic. Alogliptin is not recommended in members with or at risk for heart failure. Consider Tradjenta in these cases.

**Syringes/pen needles:** Pen needles allowed if history of insulin pens are found, syringes if history of vials.

**Authorization submission:** Please submit TARs via the Provider portal. <https://provider.kernfamilyhealthcare.com>  
Contact your company's system administrator for user access. If you are unsure who your system administrator is, please contact your Kern Health Systems Provider Relations Representative.

Sincerely,

Bruce Wearda, R.Ph.  
Director of Pharmacy